Fulcrum Therapeutics Inc. (FULC)
The price, the headline numbers and the latest news, in one place.
Fulcrum Therapeutics Inc. (FULC) Stock Price, Analysis & Data
| Bid | 2.71 |
| Market Cap | 294.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -85M |
| 2.58 | |
| -1.22 | |
| n/a | |
| -7.91 | |
| P/B (ttm) | 0.95 |
| P/S (ttm) | n/a |
| Earnings Date | Oct 29, 2026 |
| Ask | 4.78 |
| Volume | 1,320,063 |
| Avg. Volume (20D) | 2,872,033 |
| Open | 3.87 |
| Previous Close | 3.84 |
| Day's Range | 3.83 - 3.89 |
| 52-Week Range | 2.83 - 15.74 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the tr...
Financial Performance
In 2025, Fulcrum Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 80M. Earnings were -74.88M, an increase of 669.97%.
Financial StatementsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.22 misses estimates by 0.00, with 21.43% YoY growth.
Analysts project revenue of ... Upgrade
1 week ago · Pharmaceutical Technology
Fulcrum and Slate Medicines sign merger agreementAfter completion of the merger, the combined company will develop Slate’s migraine treatment pipeline.
